Literature DB >> 21175572

Trapping and dissociation of propafenone derivatives in HERG channels.

A Windisch1, En Timin, T Schwarz, D Stork-Riedler, T Erker, Gf Ecker, S Hering.   

Abstract

BACKGROUND AND
PURPOSE: Human ether-a-go-go related gene (HERG) channel inhibitors may be subdivided into compounds that are trapped in the closed channel conformation and others that dissociate at rest. The structural peculiarities promoting resting state dissociation from HERG channels are currently unknown. A small molecule-like propafenone is efficiently trapped in the closed HERG channel conformation. The aim of this study was to identify structural moieties that would promote dissociation of propafenone derivatives. EXPERIMENTAL APPROACH: Human ether-a-go-go related gene channels were heterologously expressed in Xenopus oocytes and potassium currents were recorded using the two-microelectrode voltage clamp technique. Recovery from block by 10 propafenone derivatives with variable side chains, but a conserved putative pharmacophore, was analysed. KEY
RESULTS: We have identified structural determinants of propafenone derivatives that enable drug dissociation from the closed channel state. Propafenone and four derivatives with 'short' side chains were trapped in the closed channel. Five out of six bulky derivatives efficiently dissociated from the channel at rest. One propafenone derivative with a similar bulk but lacking an H-bond acceptor in this region was trapped. Correlations were observed between molecular weight and onset of channel block as well as between pK(a) and recovery at rest. CONCLUSION AND IMPLICATIONS: The data show that extending the size of a trapped HERG blocker-like propafenone by adding a bulky side chain may impede channel closure and thereby facilitate drug dissociation at rest. The presence of an H-bond acceptor in the bulky side chain is, however, essential.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21175572      PMCID: PMC3057292          DOI: 10.1111/j.1476-5381.2010.01159.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  32 in total

1.  Structural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance.

Authors:  P Chiba; G Ecker; D Schmid; J Drach; B Tell; S Goldenberg; V Gekeler
Journal:  Mol Pharmacol       Date:  1996-06       Impact factor: 4.436

2.  The hERG potassium channel and drug trapping: insight from docking studies with propafenone derivatives.

Authors:  Khac-Minh Thai; Andreas Windisch; Daniela Stork; Anna Weinzinger; Andrea Schiesaro; Robert H Guy; Eugen N Timin; Steffen Hering; Gerhard F Ecker
Journal:  ChemMedChem       Date:  2010-03-01       Impact factor: 3.466

3.  Single HERG delayed rectifier K+ channels expressed in Xenopus oocytes.

Authors:  A Zou; M E Curran; M T Keating; M C Sanguinetti
Journal:  Am J Physiol       Date:  1997-03

4.  Open channel block of HERG K(+) channels by vesnarinone.

Authors:  K Kamiya; J S Mitcheson; K Yasui; I Kodama; M C Sanguinetti
Journal:  Mol Pharmacol       Date:  2001-08       Impact factor: 4.436

Review 5.  I(Kr): the hERG channel.

Authors:  G N Tseng
Journal:  J Mol Cell Cardiol       Date:  2001-05       Impact factor: 5.000

6.  Structural determinants of HERG channel block by clofilium and ibutilide.

Authors:  Matthew Perry; Marcel J de Groot; Ray Helliwell; Derek Leishman; Martin Tristani-Firouzi; Michael C Sanguinetti; John Mitcheson
Journal:  Mol Pharmacol       Date:  2004-08       Impact factor: 4.436

7.  The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.

Authors:  Harry J Witchel; Christopher E Dempsey; Richard B Sessions; Matthew Perry; James T Milnes; Jules C Hancox; John S Mitcheson
Journal:  Mol Pharmacol       Date:  2004-08-12       Impact factor: 4.436

8.  A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel.

Authors:  M C Sanguinetti; C Jiang; M E Curran; M T Keating
Journal:  Cell       Date:  1995-04-21       Impact factor: 41.582

9.  Molecular and structural basis of resting and use-dependent block of sodium current defined using disopyramide analogues.

Authors:  J Z Yeh; R E TenEick
Journal:  Biophys J       Date:  1987-01       Impact factor: 4.033

10.  Molecular determinants of HERG channel block.

Authors:  Kaichiro Kamiya; Ryoko Niwa; John S Mitcheson; Michael C Sanguinetti
Journal:  Mol Pharmacol       Date:  2006-02-10       Impact factor: 4.436

View more
  11 in total

Review 1.  Translational toxicology and rescue strategies of the hERG channel dysfunction: biochemical and molecular mechanistic aspects.

Authors:  Kai-ping Zhang; Bao-feng Yang; Bao-xin Li
Journal:  Acta Pharmacol Sin       Date:  2014-11-24       Impact factor: 6.150

2.  Kv 11.1 (hERG)-induced cardiotoxicity: a molecular insight from a binding kinetics study of prototypical Kv 11.1 (hERG) inhibitors.

Authors:  Z Yu; A P IJzerman; L H Heitman
Journal:  Br J Pharmacol       Date:  2014-12-15       Impact factor: 8.739

3.  The CatSper channel: a polymodal chemosensor in human sperm.

Authors:  Christoph Brenker; Normann Goodwin; Ingo Weyand; Nachiket D Kashikar; Masahiro Naruse; Miriam Krähling; Astrid Müller; U Benjamin Kaupp; Timo Strünker
Journal:  EMBO J       Date:  2012-02-21       Impact factor: 11.598

4.  In silico analysis of conformational changes induced by mutation of aromatic binding residues: consequences for drug binding in the hERG K+ channel.

Authors:  Kirsten Knape; Tobias Linder; Peter Wolschann; Anton Beyer; Anna Stary-Weinzinger
Journal:  PLoS One       Date:  2011-12-15       Impact factor: 3.752

5.  Inhibition of hERG potassium channel by the antiarrhythmic agent mexiletine and its metabolite m-hydroxymexiletine.

Authors:  Roberta Gualdani; Francesco Tadini-Buoninsegni; Mariagrazia Roselli; Ivana Defrenza; Marialessandra Contino; Nicola Antonio Colabufo; Giovanni Lentini
Journal:  Pharmacol Res Perspect       Date:  2015-07-31

6.  Correlation between human ether-a-go-go-related gene channel inhibition and action potential prolongation.

Authors:  P Saxena; M P Hortigon-Vinagre; S Beyl; I Baburin; S Andranovits; S M Iqbal; A Costa; A P IJzerman; P Kügler; E Timin; G L Smith; S Hering
Journal:  Br J Pharmacol       Date:  2017-08-11       Impact factor: 9.473

7.  How to solve the problems of docking into a symmetric binding site: the example of the HERG channel.

Authors:  Andrea Schiesaro; Lars Richter; Gerhard F Ecker
Journal:  Sci Pharm       Date:  2013-07-31

8.  Drug trapping in hERG K+ channels: (not) a matter of drug size?

Authors:  Tobias Linder; Harald Bernsteiner; Priyanka Saxena; Florian Bauer; Thomas Erker; Eugen Timin; Steffen Hering; Anna Stary-Weinzinger
Journal:  Medchemcomm       Date:  2015-12-22       Impact factor: 5.121

9.  A computational model predicts adjunctive pharmacotherapy for cardiac safety via selective inhibition of the late cardiac Na current.

Authors:  Pei-Chi Yang; Nesrine El-Bizri; Lucia Romero; Wayne R Giles; Sridharan Rajamani; Luiz Belardinelli; Colleen E Clancy
Journal:  J Mol Cell Cardiol       Date:  2016-08-18       Impact factor: 5.000

10.  New potential binding determinant for hERG channel inhibitors.

Authors:  P Saxena; E-M Zangerl-Plessl; T Linder; A Windisch; A Hohaus; E Timin; S Hering; A Stary-Weinzinger
Journal:  Sci Rep       Date:  2016-04-12       Impact factor: 4.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.